GEMINA LABORATORIES LTD. Financials Gemina Laboratories Ltd.
Equities
GLAB
CA3686501071
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 CAD | 0.00% |
|
-11.11% | -25.93% |
| 05-31 | Gemina Laboratories Ltd. Reports Earnings Results for the Full Year Ended January 31, 2024 | CI |
| 04-02 | Gemina Laboratories Sign First Strategic License Agreement | CI |
Valuation
| Fiscal Period: January | 2022 | 2023 | 2024 |
|---|---|---|---|
| Capitalization 1 | 27.47 | 44.87 | 41.06 |
| Enterprise Value (EV) 1 | 26.36 | 45.03 | 41.55 |
| P/E ratio | -5.03 x | -7.05 x | -7.78 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -5,583,864 x | -7,548,311 x | -8,027,102 x |
| EV / FCF | -9,687,634 x | -19,122,384 x | -29,567,013 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 29.4 x | -642 x | -25.9 x |
| Nbr of stocks (in thousands) | 54,936 | 64,099 | 73,326 |
| Reference price 2 | 0.5000 | 0.7000 | 0.5600 |
| Announcement Date | 5/31/22 | 5/31/23 | 5/30/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: January | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA | - | -4.72 | -5.965 | -5.176 |
| EBIT 1 | -0.6697 | -4.734 | -5.98 | -5.198 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -1.112 | -4.735 | -5.979 | -5.217 |
| Net income 1 | -1.112 | -4.735 | -5.979 | -5.217 |
| Net margin | - | - | - | - |
| EPS 2 | -0.0330 | -0.0994 | -0.0993 | -0.0720 |
| Free Cash Flow | - | -2.721 | -2.355 | -1.405 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 7/28/21 | 5/31/22 | 5/31/23 | 5/30/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: January | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net Debt 1 | - | - | 0.16 | 0.48 |
| Net Cash position 1 | 0.78 | 1.11 | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.0264 x | -0.0936 x |
| Free Cash Flow | - | -2.72 | -2.35 | -1.41 |
| ROE (net income / shareholders' equity) | - | -858% | -1,371% | 630% |
| ROA (Net income/ Total Assets) | - | -150% | -227% | -195% |
| Assets 1 | - | 3.158 | 2.636 | 2.675 |
| Book Value Per Share 2 | 0 | 0.0200 | -0 | -0.0200 |
| Cash Flow per Share 2 | 0.0200 | 0.0200 | 0 | 0 |
| Capex | - | 0.01 | 0.08 | 0.04 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 7/28/21 | 5/31/22 | 5/31/23 | 5/30/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -25.93% | 21.42M | |
| -10.29% | 11.38B | |
| -20.75% | 6.83B | |
| +5.45% | 5.52B | |
| +28.32% | 5.44B | |
| -21.94% | 3.62B | |
| +6.32% | 2.56B | |
| -66.49% | 2.26B | |
| +30.36% | 2.24B | |
| -12.28% | 2.13B |
- Stock Market
- Equities
- GLAB Stock
- Financials Gemina Laboratories Ltd.
